Purple Biotech
PPBT
5 hedge funds and large institutions have $242K invested in Purple Biotech in 2018 Q2 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
332% more capital invested
Capital invested by funds: $56K → $242K (+$186K)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
67% more funds holding
Funds holding: 3 → 5 (+2)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$120K |
| 2 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$45K |
| 3 |
VF
Virtu Financial
New York
|
+$30K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$23K |
| 2 |
AG
Advisor Group
Phoenix,
Arizona
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $128K | +$120K | +24 | New |
|
|
EIM
2
Essex Investment Management
Boston,
Massachusetts
| $47K | +$45K | +9 | New |
|
|
VF
3
Virtu Financial
New York
| $31K | +$30K | +6 | New |
|
4
Wells Fargo
San Francisco,
California
| $26K | – | – | – |
|
5
UBS Group
Zurich,
Switzerland
| $10K | – | – | – |
|
|
TSS
6
Two Sigma Securities
New York
| – | -$23K | -5 | Closed |
|
|
AG
7
Advisor Group
Phoenix,
Arizona
| – | -$1K | – | – |
|
PPBT Hedge Fund Activity: Q2 2018 in Review
5 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Purple Biotech (PPBT) for Q2 2018, worth a combined $242K — up 332% from $56K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new PPBT positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $120K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $23K sold.
- 5 institutional investors held Purple Biotech (PPBT) as of Q2 2018, up from 3 in Q1 2018.
- Funds reported $242K of Purple Biotech stock for Q2 2018, up 332% quarter-over-quarter.
- 3 funds opened new Purple Biotech positions in Q2 2018 and 1 closed out, a net change of +2 holders.
- The largest Purple Biotech buyer in Q2 2018 was Morgan Stanley, an estimated $120K added.
- The largest Purple Biotech seller in Q2 2018 was Two Sigma Securities, an estimated $23K sold.
Based on aggregated 13F filings for Q2 2018.